Navigation Links
Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate
Date:12/21/2010

PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem® (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy."  The new patent, number 7,851,506, is also listed in the FDA's Approved Drug Products List (the Orange Book).  

In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product's formulation and Jazz Pharmaceuticals' distribution system.  Six issued patents are now listed in the Orange Book.  These patents expire from 2019 to 2024.

"Enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, Jazz Pharmaceuticals' intent to vigorously enforce its intellectual property rights.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to protect its intellectual property and defend its patents, the possible introduction of generic products, the dependence of the company on sales of Xyrem, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 5, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
2. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
3. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
4. Lotus Pharmaceuticals Announces Change of Directors
5. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
6. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
7. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
8. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. John A. MacPhee Resigns From Strativa Pharmaceuticals
10. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
11. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial ... 2017, and updated its financial outlook for fiscal 2017. ... fiscal third quarter, Hill-Rom reported earnings of $0.09 per ... the prior-year period. These results reflect after-tax special items, ... related to the non-cash write-down of assets associated with ...
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... Raleigh, North Carolina (PRWEB) , ... August 22, ... ... senior strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 ... elements that have become critical to his definition of “success”: physician leadership development, ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides online resources ... physicians and advanced practitioners like nurse practitioners and physician assistants , ... November of this year. The online career fairs will allow job seekers to connect ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... FCPX LUT ... Editors can quickly and easily add washed color grades to footage. A LUT ... LUT changes every pixel’s color to the corresponding color indicated by the table. This ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... involvement program serving the people of Michigan. The new initiative fundraises for the ... at the very forefront of animal protection and welfare by addressing the root ...
Breaking Medicine News(10 mins):